Sanofi GCVRZ 深 滬
已收盤 03-26 16:00:00 美东时间
0.8711
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.8711
- 總市值 1113.52亿
- 52周最高 0.882
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.43
- 委 比 0.00%
- 總股本 1278.30亿
- 歷史最高 0.882
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.153
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Sanofi Reaches Agreement With Trump Administration To Reduce Medicine Costs
Sanofi today announced an agreement with President Donald J. Trump's Administration to help ensure American patients have access to more affordable medicines while also supporting the role of the US in biopharmaceutical
今天 03:24
Sanofi Expands Real‑World Atopic Dermatitis Data With Global Long‑Term Registry
Sanofi SA ($SNY) announced an update on their ongoing clinical study. Study Ove...
12-19 00:32
White House Readies Drug Price Deals With AbbVie, Novartis, Roche
AbbVie and other drugmakers may announce U.S. drug pricing deals on Friday as the White House pushes lower prices and Medicare payment reforms.
12-18 23:14
Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy
Cytokinetics announced the approval of MYQORZO® (aficamten) by China's NMPA for treating adults with NYHA class II-III obstructive hypertrophic cardiomyopathy (oHCM). Under its agreement with Sanofi, the approval triggers a $7.5 million milestone payment to Cytokinetics, with potential for up to $142.5 million in additional payments and royalties for sales in Greater China. MYQORZO is currently under regulatory review in the U.S. and has received...
12-17 12:30
Pfizer leads COVID-19 vaccine peers lower after revamped guidance
A slightly disappointing revenue outlook from Pfizer (PFE) was enough for its COVID-19 vaccine rivals Moderna (MRNA) and Novavax (NVAX) to trade lower on Tuesday, just as a major safety scare related ...
12-17 02:37
Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration
Sanofi expands its partnership with Dren Bio in a deal featuring $100 million upfront and up to $1.7 billion tied to a next-generation autoimmune B-cell therapy.
12-16 02:10
Canopy Growth To Acquire MTL Cannabis
Canopy Growth Corp. (NASDAQ: CGC) to acquire MTL Cannabis Corp. (OTCQX: MTLNF) for approx. 125 million CAD in cash and stock.
12-16 00:28
Cencora Strikes $5 Billion OneOncology Deal, Pauses Stock Buyback
Cencora agrees to buy a majority stake in OneOncology for about $5 billion, pauses buybacks, and reiterates fiscal 2026 sales and EPS guidance.
12-15 22:09
Sanofi's Multiple Sclerosis Drug Faces Trial And Regulatory Setbacks
Sanofi said its Phase 3 PERSEUS trial of tolebrutinib missed the primary endpoint in PPMS, ending plans for regulatory filing.
12-15 20:52
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Scientists developed an antibody treatment that reawakens the immu...
12-12 23:47
